文献速递慢病管理老年与多病共存

痛风管理与长期血尿酸控制:基于人群的基层医疗队列研究

Management and long-term serum urate control in gout: a population-based primary care cohort study.
PubMed 文献 · Br J Gen Pract · 2026-07-30

该回顾性队列纳入2012至2023年确诊的94 759例痛风患者,评估基层医疗中痛风治疗模式与长期血尿酸控制情况。仅12.40%患者达到良好血尿酸控制(随访≥80%时间SU<6 mg/dL),且随时间无改善;37.30%从未接受降尿酸治疗。早期启动降尿酸治疗、剂量优化与提高依从性是改善管理的关键可干预靶点。

要点

  • 仅12.40%痛风患者达到长期良好血尿酸控制,且无随时间改善趋势。
  • 37.30%患者从未接受降尿酸治疗,15.92%治疗持续时间≤25天。
  • 延迟启动治疗、男性、肥胖、慢性肾病、血脂异常和高血压与控制不佳相关。

核心结论

  • 基层医疗中痛风患者长期血尿酸控制欠佳,仅12.40%达到良好控制且无改善趋势。
  • 早期启动降尿酸治疗、适当剂量优化和改善依从性是改善痛风管理的关键可干预靶点。

研究设计与样本

  • 回顾性基于人群的队列研究,使用覆盖加泰罗尼亚超过75%人口的基层医疗研究数据库SIDIAP。
  • 纳入2012至2023年诊断为痛风的新发患者94 759例,平均年龄66.25岁(标准差14.64),男性占79.58%,中位随访5.44年(四分位距2.54-8.24)。

主要发现

  • 合并症常见:高血压65.15%、血脂异常50.58%、糖尿病24.19%、慢性肾病32.80%。
  • 88.95%患者至少有一次血尿酸测量,37.30%从未接受降尿酸治疗。
  • 接受治疗者中96.09%以别嘌醇为初始治疗,仅12.40%达到良好血尿酸控制。
  • 15.92%患者降尿酸治疗持续时间≤25天。
  • 良好控制与更长治疗时间、更高别嘌醇剂量、非布司他使用和更好依从性相关;延迟启动降尿酸治疗、男性、肥胖、慢性肾病、血脂异常和高血压与控制不佳相关。

关键数值与推荐

  • 良好血尿酸控制定义为随访时间≥80%期间血尿酸水平<6 mg/dL。

临床怎么用

  • 对痛风患者应早期启动降尿酸治疗,避免延迟。
  • 治疗中注意适当优化别嘌醇剂量,并评估依从性。
  • 对合并肥胖、慢性肾病、血脂异常、高血压的男性患者应加强血尿酸监测与控制。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gout is a prevalent chronic inflammatory disease associated with a substantial clinical and cardiovascular burden. Despite the availability of effective urate-lowering therapies (ULTs), gout management remains suboptimal. AIM: To describe clinical characteristics and treatment patterns, and to identify factors associated with long-term serum urate (SU) control in gout. DESIGN AND SETTING: Retrospective population-based cohort study using the primary care research database 'Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària' (SIDIAP), covering >75% of the Catalan population within a universal healthcare system. METHOD: Individuals with incident gout diagnosed between 2012 and 2023 were included. Demographic, clinical, and ULT data were collected. Good SU control was defined as SU levels <6 mg/dL for ≥80% of follow-up time. Factors associated with SU control were analysed. RESULTS: A total of 94 759 patients were included (mean age 66.25 [standard deviation 14.64] years; 79.58% male [75 412/94 759]; median follow-up 5.44 [interquartile range 2.54-8.24] years). In the 94 759 patients, hypertension (65.15%, n = 61 732), dyslipidaemia (50.58%, n = 47 932), diabetes (24.19%, n = 22 919), and chronic kidney disease (32.80%, 27 013/82 270 ) were common. Of the patients, 88.95% (n = 84 288) had ≥1 SU measurement. In total, 37.30% (35 343/94 759) had never received ULT. Allopurinol was the initial therapy in 96.09% of treated patients. Only 12.40% (10 453/84 288) achieved good SU control, with no improvement over time. Short ULT duration (≤25 days) occurred in 15.92% (9459/59 416) of patients. Good control was associated with longer treatment duration, higher allopurinol doses, febuxostat use, and better adherence, whereas delayed ULT initiation, male sex, obesity, chronic kidney disease, dyslipidaemia, and hypertension were associated with poor control. CONCLUSION: Long-term SU control in gout remains poor in primary care. Early initiation of ULT, appropriate dose optimisation, and improved adherence represent key modifiable targets to improve gout management.

来源:Br J Gen Pract,查看原文。版权归原作者所有。

引用

  1. Pou MA, Reyes C, Martinez-Laguna D, et al. Management and long-term serum urate control in gout: a population-based primary care cohort study. Br J Gen Pract. 2026. PMID: 42242878. doi:10.3399/BJGP.2025.0788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。